EMLA cream application without occlusive dressing before upper facial botulinum toxin injection: a randomized, double-blind, placebo-controlled trial.
A randomized, double-blind, placebo-controlled clinical trial was conducted among 44 subjects to assess the efficacy of EMLA cream application without occlusive dressing on pain on needling (PN) and pain on injection (PI) felt during multiple botulinum toxin type A (BTA) injections for correction of hyperkinetic upper facial lines. Mean PN score was less than PI score with high correlation and no significant difference. Although both PN and PI scores (visual analog) were less in the EMLA than placebo group, the difference was only statistically significant for PN score. Time intervals between the cream application and BTA injections beyond 60 minutes did not show lower pain score in either type of the pain.
Kashkouli
Mohsen Bahmani
MB
Rassoul Akram Hospital, Iran. bahmanik@yahoo.com
Salimi
Shabnam
S
Bakhtiari
Pejman
P
Parvaresh
Mohammad Mehdi
MM
Sanjari
Mostafa Soltan
MS
Naseripour
Masood
M
D000328:Adult; D000779:Anesthetics, Local / Q000008:administration & dosage*; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004311:Double-Blind Method; D005145:Face; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage*; D000077442:Lidocaine, Prilocaine Drug Combination; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D009824:Ointments; D010147:Pain Measurement; D011318:Prilocaine / Q000008:administration & dosage*; D011446:Prospective Studies; D015595:Skin Aging / Q000187:drug effects*
D000779:Anesthetics, Local; D000077442:Lidocaine, Prilocaine Drug Combination; D009465:Neuromuscular Agents; D009824:Ointments; D011318:Prilocaine; D008012:Lidocaine; D019274:Botulinum Toxins, Type A